Immunotherapy for Infectious Diseases

258 Onorato and Pollard
26. Guidotti LG, Guihlot S, Chisari FV. Interleukin 2 and interferon alpha/beta downregulate
hepatitis B virus gene expression in vivo by tumor necrosis factor—dependent and independent
pathways. J Virol 1994; 68:1265–1270.
27. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus
gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA
1994; 91:3764–3768.
28. Paar DP, Montgomerie BM, Nadler P, Schiff ER, Pollard RB. A phase I/II open-label trial
to assess the safety, pharmacokinetic profile, and preliminary antiviral effects of OST-577
(a human monoclonal anti-hepatitis B surface antigen monoclonal antibody) administered
to patients who are persistently hepatitis B surface antigen seropositive. In: Proceedings of
the International Society for Antiviral Research, Charleston, SC, 1994 (Abstract).
29. Meyers JD. Prevention of cytomegalovirus infection after marrow transplantation. Rev
Infect Dis 1989; 11:S1691–S1705.
30. Snydmena DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin
to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;
317:1049–1054.
31. Lakeman F, Blevins BS, Whitley R, Tolpin M. In vitro neutralization of CMV strains by
human monoclonal antibody, MSL 109. Antiviral Res 1991; 15:77.
32. Nokta MA, Tolpin MD, Nadler PI, Pollard RB. Human monoclonal anti-CMV antibody
(MSL 109): enhancement of in vitro foscarnet and ganciclovir induced inhibition of CMV
replication. Antiviral Res 1994; 24:17–26.
33. Tolpin M, Pollard RB, Tierney M, Nokta MA, Wood D, Hirsch M. Combination therapy of
CMV retinitis with a human monoclonal antibody (SDZ MSL 109) and either ganciclovir
or foscarnet. In: Proceedings of the IX International Conference on AIDS. 1993 (Abstract).
34. The Studies of Ocular Complications of AIDS Research Group. MSL 109 adjuvant therapy
for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the
monoclonal antibody cytomegalovirus retinitis trial. Arch Ophthalmol 1997; 115:1528–1536.
35. Reed ED, Bowden RA, Dandliker PS, Lilleby KE, Myers JD. Treatment of cytomegalovirus
pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients
with bone marrow transplants. Ann Intern Med 1988; 109:783–788.
36. Emmanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone
marrow transplant successfully treated with the combination of ganciclovir and high-dose
intravenous immune globulin. Ann Intern Med 1988; 109:777–782.
37. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic lymphocyte response to
cytomegalovirus after human allogenic bone marrow transplantation: patterns of recovery
and correlation with cytomegalovirus infection and disease. Blood 1991; 78:1373–1380.
38. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against
cytomegalovirus in recipients of allogenic bone marrow by transfer of T-cell clones from
the donor. N Engl J Med 1995; 333:1038–1044.
39. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted
cytomegalovirus-specific T-cell responses after allogeneic bone marrow transplant; correlation
with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83:1971–1979.